•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
OPNT will NOT be doing a secondary option anytime soon if at all. Companies that practice this move are companies that are hurting for cash and have no source of revenue. Which is the exact opposite of OPNT. They have a source of revenue, zero debt, and 10 mil in cash that doesn't include the recent payment of 3.75mil. If they wanted to get a handle on their low float they would more than likely do a split of 5 to 1 around the time the stock was trading in the 40-50 range
I have been long holder of OPNT and recently sold for some profit. I still believe in long-term prospects, but with such few outstanding shares, dramatic price rise, and stock options ready to be exercised, now would be a good time for them to do an offering, diluting share price. The market cap is small tho, so even after dilution, room for upside remains. Good luck everyone, glad to see OPNT finally start receiving recognition.
Has everyone received "the" phone call yet? It's coming.
Addition revenue for OPNT: The Narcan dosages distributed come in packs of two, and while they normally retail for about $75, a donation from the tech company Leidos is the reason everyone was able to walk out with one for free Saturday.
Leidos CEO Roger Krone said he first learned about the problem with opioid addiction from an employee who lost a son.
If more company involve in this kind of community awareness that's additional revenue for this company. I think NARCAN royalty will pay off SWK well ahead of time.
Does anyone else find it ironic that Opiant's success relies on the opiate abuse remaining high?
Not sure why people are so concern about dilution (which company give no indication). NARCAN drug is showing up everywhere and saving everyday. I think Walgreen and CVS are start carrying this drug and first responded and hospitals are using in very high demand. You have to look at bigger picture. I think company calculated pipeline cost and burn rate and came up with ~$17M number which they got it from SWK. But, now looking at NARCAN demand I think they will achieve their target goal well ahead of time and may not need additional fund till next FDA approval.
Doctors treat Indiana toddler with Narcan after opiate overdose
Police say doctors treated a central Indiana toddler with the overdose reversal drug Narcan after he apparently ingested opiates that he found.
I don't have a position in OPNT, have been watching it for a week or so. Although there is demand for NARCAN but I don't agree with the notion that a prescription for NARCAN will be written with every prescription of Opiod. That is like thinking that each time someone buys a box of matches he will also buy a fire extinguisher!! Good luck to all.
Nice reversal......going green for the day. I was wondering who was selling? I probably won't even start thinking about taking profit until it hits around $50.
Different between life and death. This drug is getting really good traction and media coverage.
*Andrew, an HVAC engineer, looks better than your average 37-year-old, college-educated man from Canton, OH. Clean-shaven, wearing a fitted maroon polo shirt and black dress pants. Athletic. Energetic. Flirtatious. He sits on the patio of a local res
In the article below, the doctor that saved her life states that doses of NARCAN should be on board every flight.
Very noble idea. Really good for OPNT. You guys can read through article and if you agree with thought process their is a link to sign petition..
Lyft And Uber Drivers Could Help Fight The Drug Epidemic With One Simple Tool
Most drivers aren’t prepared for this situation, but they’re in a unique position to save a life.
He had point but, just take his example. Every house has fire extinguisher and need to check if it's in working condition all the time. Same for NARCAN spray, even you don't use it but, every prescription user should have that and make sure it's not expire. That's alone will make company worth around $100M. I haven't touch about AUD which has around $350M market cap, BN has another $200M to $300M mapket cap. If this company only grab 10% of overall market that means company worth around $150-$200M. Apart from that, this company has good momentum so, nothing wrong to be on positive side of momentum.
Nice sell off in to close..
It was fun while it lasted but volume has dried up and I didn't like the responses (or lack there of) from the investors relation people at Argot. I'm getting the impression shareholder's are not top priority and a dilution is coming shortly. I will keep my eyes open for another entry point but I'm thing sub $15.